8-K   

UNITED STATES  

SECURITIES AND EXCHANGE COMMISSION  

Washington, D.C. 20549  

FORM 8-K  

CURRENT REPORT  

Pursuant to Section 13 OR 15(d)  

of The Securities Exchange Act Of 1934  

Date of Report (Date of earliest event reported): February 27, 2015 (February 23, 2015)  

BRISTOL-MYERS SQUIBB COMPANY  

(Exact Name of Registrant as Specified in its Charter)  

  [DATA_TABLE_REMOVED] 

345 Park Avenue  

New York, NY, 10154  

(Address of Principal Executive Office)  

Registrant’s telephone number, including area code: (212) 546-4000  

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):  

 ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  

 ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  

 ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  

 ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  

 Item 8.01. Other Events.  

On February 23, 2015, Bristol-Myers Squibb Company (the “Company”) and Flexus Biosciences, Inc. issued a joint press release announcing that the companies have signed a definitive agreement under which the Company will acquire all of the outstanding capital stock of Flexus Biosciences, Inc., a privately held biotechnology company focused on the discovery and development of novel anti-cancer therapeutics, for a potential total consideration of $1.25 billion, including $800 million upfront and development milestones that, upon achievement, could total up to $450 million. A copy of the press release announcing the planned acquisition is filed as Exhibit 99.1 to this report and is incorporated herein by reference.  

 Item 9.01. Financial Statements and Exhibits.  

(d) Exhibits.  

 99.1  Press release of Bristol-Myers Squibb Company dated February 23, 2015.  

SIGNATURES  

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.  

  [DATA_TABLE_REMOVED] 

EXHIBIT INDEX  

  Exhibit

No.    Description 

 99.1   Press release of Bristol-Myers Squibb Company dated February 23, 2015.